|
|
 |
|
|
|
|
A-II antagonists, 20 |
|
|
|
|
|
|
|
|
Absorption enhancer, 9 |
|
|
|
|
|
|
|
|
Academicians, 12 |
|
|
|
|
|
|
|
|
ACE inhibitors, 20, 24, 26, 28 |
|
|
|
|
|
|
|
|
Action Potential Duration (APD), 23 |
|
|
|
|
|
|
|
|
Amiodarone, 7 |
|
|
|
|
|
|
|
|
Anticancer drugs, 282-293 |
|
|
|
|
|
|
|
|
animal toxicology of, 284-285 |
|
|
|
|
|
|
|
|
dose escalation schemes, 287-289 |
|
|
|
|
|
|
|
|
phase I trials, 285-290 |
|
|
|
|
|
|
|
|
phase II trials, 290-291 |
|
|
|
|
|
|
|
|
phase III trials, 291-292 |
|
|
|
|
|
|
|
|
Bayh-Dole Act, 61 |
|
|
|
|
|
|
|
|
Biodiversity, 5 |
|
|
|
|
|
|
|
|
Bioinformatics, 209 |
|
|
|
|
|
|
|
|
Biotechnology, 8 |
|
|
|
|
|
|
|
|
Biotechnology Patent Protection Act, 62 |
|
|
|
|
|
|
|
|
Botanicals, 3-5 |
|
|
|
|
|
|
|
|
Brookhaven Protein Database (PDB), 215 |
|
|
|
|
|
|
|
|
Cambridge Crystallographic Database (CSD), 214 |
|
|
|
|
|
|
|
|
Celluloses, 125 |
|
|
|
|
|
|
|
|
Central laboratory, 384, 395-400 |
|
|
|
|
|
|
|
|
establishing in Europe, 399-400 |
|
|
|
|
|
|
|
|
operational pretrial checks at, 412-414 |
|
|
|
|
|
|
|
|
Chemical discovery, 6 |
|
|
|
|
|
|
|
|
Chronobiology, 190 |
|
|
|
|
|
|
|
|
Clinical pathology and clinical trials, 380-381 |
|
|
|
|
|
|
|
|
laboratories, 384-386 |
|
|
|
|
|
|
|
|
laboratory at Zeneca, 388-394, 401-404, 408-411, 415 |
|
|
|
|
|
|
|
|
and preclinical studies, 379-380 |
|
|
|
|
|
|
|
|
role in drug development process, 379-384 |
|
|
|
|
|
|
|
|
support of Phase I trials, 394-395 |
|
|
|
|
|
|
|
|
support of Phase II and III trials, 395-400 |
|
|
|
|
|
|
|
|
testing in Europe, 379-420 |
|
|
|
|
|
|
|
|
Clinical pharmacology, 267-270, 296 |
|
|
|
|
|
|
|
|
Clinical trials, 10, 32 |
|
|
|
|
|